Literature DB >> 18493245

Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling.

A Baartscheer1, M Hardziyenka, C A Schumacher, C N W Belterman, M M G J van Borren, A O Verkerk, R Coronel, J W T Fiolet.   

Abstract

BACKGROUND AND
PURPOSE: Increased activity of the Na+/H+ -exchanger (NHE-1) in heart failure underlies raised [Na+]i causing disturbances of calcium handling. Inhibition of NHE-1, initiated at the onset of pressure/volume overload, prevents development of hypertrophy, heart failure and remodelling. We hypothesized that chronic inhibition of NHE-1, initiated at a later stage, would induce regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling. EXPERIMENTAL APPROACH: Development of heart failure in rabbits was monitored electrocardiographically and echocardiographically, after one or three months. Cardiac myocytes were also isolated. One group of animals were treated with cariporide (inhibitor of NHE-1) in the diet after one month. Cytoplasmic calcium, sodium and action potentials were measured with fluorescent markers and sarcoplasmic reticulum calcium content by rapid cooling. Calcium after-transients were elicited after rapid pacing. Sodium channel current (INa) was measured using patch-clamp techniques. KEY
RESULTS: Hypertrophy and heart failure developed after one month and progressed during the next two months. After one month, dietary treatment with cariporide was initiated. Two months of treatment reduced hypertrophy and heart failure, duration of action potential QT-interval and QRS, and restored sodium and calcium handling and the incidence of calcium after-transients. In cardiac myocytes, parameters of INa were not changed by cariporide. CONCLUSION AND IMPLICATIONS: In rabbit hearts with hypertrophy and signs of heart failure one month after induction of pressure/volume overload, two months of dietary treatment with the NHE-1 inhibitor cariporide caused regression of hypertrophy, heart failure and ionic and electrophysiological remodelling.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493245      PMCID: PMC2483399          DOI: 10.1038/bjp.2008.189

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  36 in total

1.  Endothelin-1 stimulates the Na+/Ca2+ exchanger reverse mode through intracellular Na+ (Na+i)-dependent and Na+i-independent pathways.

Authors:  Ernesto Alejandro Aiello; María Celeste Villa-Abrille; Raúl Ariel Dulce; Horacio Eugenio Cingolani; Néstor Gustavo Pérez
Journal:  Hypertension       Date:  2004-12-20       Impact factor: 10.190

Review 2.  Genomics and the pathophysiology of heart failure.

Authors:  J J Hwang; V J Dzau; C C Liew
Journal:  Curr Cardiol Rep       Date:  2001-05       Impact factor: 2.931

3.  Chronic heart failure slows late sodium current in human and canine ventricular myocytes: implications for repolarization variability.

Authors:  Victor A Maltsev; Norman Silverman; Hani N Sabbah; Albertas I Undrovinas
Journal:  Eur J Heart Fail       Date:  2006-10-24       Impact factor: 15.534

4.  Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide.

Authors:  L Chen; X T Gan; J V Haist; Q Feng; X Lu; S Chakrabarti; M Karmazyn
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

5.  SR calcium depletion following reversal of the Na+/Ca2+-exchanger in rat ventricular myocytes.

Authors:  A Baartscheer; C A Schumacher; J W Fiolet
Journal:  J Mol Cell Cardiol       Date:  2000-06       Impact factor: 5.000

6.  Regression of cardiomyocyte hypertrophy in SHR following chronic inhibition of the Na(+)/H(+) exchanger.

Authors:  María C Camilión de Hurtado; Enrique L Portiansky; Néstor G Pérez; Oscar R Rebolledo; Horacio E Cingolani
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

7.  Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia against necrosis (GUARDIAN) Investigators.

Authors:  P Théroux; B R Chaitman; N Danchin; L Erhardt; T Meinertz; J S Schroeder; G Tognoni; H D White; J T Willerson; A Jessel
Journal:  Circulation       Date:  2000-12-19       Impact factor: 29.690

8.  Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice.

Authors:  Stefan Engelhardt; Lutz Hein; Ursula Keller; Kerstin Klämbt; Martin J Lohse
Journal:  Circ Res       Date:  2002-04-19       Impact factor: 17.367

9.  Slowly inactivating component of sodium current in ventricular myocytes is decreased by diabetes and partially inhibited by known Na(+)-H(+)Exchange blockers.

Authors:  S Chattou; A Coulombe; J Diacono; B Le Grand; G John; D Feuvray
Journal:  J Mol Cell Cardiol       Date:  2000-07       Impact factor: 5.000

10.  The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial.

Authors:  U Zeymer; H Suryapranata; J P Monassier; G Opolski; J Davies; G Rasmanis; G Linssen; U Tebbe; R Schröder; R Tiemann; T Machnig; K L Neuhaus
Journal:  J Am Coll Cardiol       Date:  2001-11-15       Impact factor: 24.094

View more
  30 in total

Review 1.  Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides.

Authors:  Camilla Calvieri; Speranza Rubattu; Massimo Volpe
Journal:  J Mol Med (Berl)       Date:  2011-08-09       Impact factor: 4.599

2.  Silencing of sodium-hydrogen exchanger 1 attenuates the proliferation, hypertrophy, and migration of pulmonary artery smooth muscle cells via E2F1.

Authors:  Lunyin Yu; Charles A Hales
Journal:  Am J Respir Cell Mol Biol       Date:  2011-03-31       Impact factor: 6.914

3.  In vivo key role of reactive oxygen species and NHE-1 activation in determining excessive cardiac hypertrophy.

Authors:  Oscar H Cingolani; Néstor G Pérez; Irene L Ennis; María C Alvarez; Susana M Mosca; Guillermo R Schinella; Eduardo M Escudero; Gloria Cónsole; Horacio E Cingolani
Journal:  Pflugers Arch       Date:  2011-08-26       Impact factor: 3.657

Review 4.  Regulation of intracellular and mitochondrial sodium in health and disease.

Authors:  Elizabeth Murphy; David A Eisner
Journal:  Circ Res       Date:  2009-02-13       Impact factor: 17.367

5.  Muscle LIM protein interacts with cofilin 2 and regulates F-actin dynamics in cardiac and skeletal muscle.

Authors:  Vasiliki Papalouka; Demetrios A Arvanitis; Elizabeth Vafiadaki; Manolis Mavroidis; Stavroula A Papadodima; Chara A Spiliopoulou; Dimitrios T Kremastinos; Evangelia G Kranias; Despina Sanoudou
Journal:  Mol Cell Biol       Date:  2009-09-14       Impact factor: 4.272

6.  Role of sodium glucose co-transporter 2 inhibitors in patients with heart failure: an elusive mechanism.

Authors:  Hafiz Imran; William Nester; Islam Y Elgendy; Marwan Saad
Journal:  Ann Med       Date:  2020-05-22       Impact factor: 4.709

Review 7.  Ion channels, transporters, and pumps as targets for heart failure therapy.

Authors:  Darshan Doshi; Steven O Marx
Journal:  J Cardiovasc Pharmacol       Date:  2009-10       Impact factor: 3.105

8.  Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress.

Authors:  Vikram Prasad; John N Lorenz; Marian L Miller; Kanimozhi Vairamani; Michelle L Nieman; Yigang Wang; Gary E Shull
Journal:  J Mol Cell Cardiol       Date:  2013-09-29       Impact factor: 5.000

9.  Regulation of ion gradients across myocardial ischemic border zones: a biophysical modelling analysis.

Authors:  Steven Niederer
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 10.  Regulation of the cardiac sodium/bicarbonate cotransporter by angiotensin II: potential Contribution to structural, ionic and electrophysiological myocardial remodelling.

Authors:  Ernesto Alejandro Aiello; Verónica Celeste De Giusti
Journal:  Curr Cardiol Rev       Date:  2013-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.